===============================================================================

                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10QSB

 -------- ---------------------------------------------------------------------
 [X]      Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
          Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2005
  -------- ---------------------------------------------------------------------
          OR
 -------- ---------------------------------------------------------------------
 [ ]      Transition Report Pursuant to Section 13 or 15(d) of the
          Securities Exchange Act of 1934
 -------- ---------------------------------------------------------------------
          For the transition period from to
 -------- ---------------------------------------------------------------------

                         COMMISSION FILE NUMBER: 0-30351

                                True Health, Inc.
             (Exact name of registrant as specified in its charter)

-------------------------------------------------- ----------------------------
     Utah                                               75-2263732
-------------------------------------------------- ----------------------------
(State of other jurisdiction                       (IRS Employer Identification
of incorporation or organization)                  Number)
-------------------------------------------------- ----------------------------

                          Kelsey House, 77 High Street
                                 Beckenham, Kent
                                   UK BR3 1AN
                    (Address of principal executive offices)

                             +(44) (0) 208 658 9575
              (Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
                           Yes [ x ]        No [ ]

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of April 30, 2005:      310,698

 ==============================================================================



<PAGE>


                                TRUE HEALTH, INC.
                           CONSOLIDATED BALANCE SHEET
                                 April 30, 2005
                                   (unaudited)


<TABLE>
ASSETS
<S>                                                                                           <C>
Current Assets
  Cash                                                                                        $    56,944
  Accounts receivable, net                                                                        556,876
  Inventory                                                                                        90,164
  Other                                                                                            37,050
                                                                                              -----------
         Total Current Assets                                                                     741,034

Equipment, net accumulated depreciation of $331,752                                               185,437
                                                                                              -----------
TOTAL ASSETS                                                                                  $   926,471
                                                                                              ===========


LIABILITIES AND STOCKHOLDERS' DEFICIT

Current Liabilities
  Note payable to factor                                                                      $   434,866
  Current portion of notes payable                                                                 58,484
  Accounts payable                                                                                 26,802
  Accrued expenses                                                                                326,594
  Amounts payable to stockholder                                                                  290,648
                                                                                              -----------
         Total Current Liabilities                                                              1,137,394

Long-term portion of notes payable                                                                 88,389
                                                                                              -----------
  Total Liabilities                                                                             1,225,783
                                                                                              -----------


Commitments     -

Stockholders' Deficit
  Convertible preferred stock, $.001 par value;
  5,000,000 shares authorized; 4,121,877 shares issued
  and outstanding                                                                                   4,122
  Common stock, $.01 par value; 100,000,000 shares
  authorized; 310,698 shares issued and outstanding                                                 3,107
  Additional paid in capital                                                                    2,163,527
  Accumulated deficit                                                                          (2,431,463)
  Accumulated other comprehensive loss                                                            (38,605)

                                                                                              -----------

  Total Stockholders' Deficit                                                                    (299,312)

                                                                                              -----------
                                                                                              $   926,471

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                                                   ===========

</TABLE>

<PAGE>


                                TRUE HEALTH, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                   Three Months Ended April 30, 2005 and 2004
                                   (unaudited)


<TABLE>
                                                                                        Three Months Ended
                                                                                   2005                 2004
                                                                                   ---------           ---------
<S>                                                                                <C>                 <C>
Revenues:
- Equipment rentals and sales                                                      $ 435,688           $ 496,375
- Recruitment services and placement fees                                            535,553           1,151,075
- Other                                                                                8,496              10,139
                                                                                   ---------           ---------
Total revenues                                                                       979,737           1,657,589
                                                                                   ---------           ---------

Cost of sales                                                                        540,383           1,061,799
General and administrative                                                           456,060             656,018
Depreciation                                                                          32,809              25,773
                                                                                   ---------           ---------
  Total operating expenses                                                         1,029,252           1,743,590
                                                                                   ---------           ---------
         Net Operating Loss                                                          (49,515)            (86,001)

Interest income                                                                            -              2,868
Interest expense                                                                     (11,838)           (5,885)
                                                                                   ---------           ---------
Net loss before taxes                                                                (61,353)          (89,019)

Income tax recovery                                                                        -                897
                                                                                   ---------           ---------
Net Loss                                                                           $ (61,353)         $ (88,122)
                                                                                   =========           =========

Basic and diluted loss
  per share                                                                        $    (.08)           $    (.10)


Weighted average shares
  outstanding                                                                        791,583            840,624

</TABLE>

<PAGE>


                                TRUE HEALTH, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                   Three Months Ended April 30, 2005 and 2004
                                   (unaudited)


<TABLE>
                                                                                        Three Months Ended
                                                                                      2005              2004
                                                                                   ----------         ----------
<S>                                                                                <C>                <C>
Cash Flows From Operating Activities
  Net loss                                                                         $  (61,353)        $  (88,122)
  Adjustments to reconcile net loss to net cash
  used in operating activities:
      Depreciation                                                                     32,809             25,773
      Imputed interest on shareholder notes payable                                     4,148             (1,822)
      Changes in:
      Accounts receivable                                                             (52,136)           (78,699)
      Inventory                                                                        56,980           (137,810)
      Other current assets                                                              4,196             52,898
      Accounts payable                                                                (82,304)           (58,116)
      Accrued expenses                                                                (27,430)            46,703
                                                                                   ----------         ----------
  Net Cash Used In Operating Activities                                              (125,090)          (239,193)
                                                                                   ----------         ----------

Cash Flows Used in Investing Activities
  Purchase of equipment                                                                     -            (30,997)
                                                                                   ----------         ----------
Cash Flows From Financing Activities
  Proceeds from exercise of warrants for stock                                              -            475,000
  Net change in stockholder advances                                                   14,055            (60,573)
  Net change in note payable to factor                                                117,866             55,600
  Proceeds on notes payable                                                            15,102                  -
  Payments on notes payable                                                           (39,398)          (125,685)
                                                                                   ----------         ----------
  Net Cash Provided By Financing Activities                                           107,625            344,342
                                                                                   ----------         ----------
Currency translation adjustment                                                         7,307              9,588
                                                                                   ----------         ----------
Net change in cash                                                                    (10,158)            83,739
Cash at beginning of period                                                            67,102            256,647
                                                                                   ----------         ----------
Cash at end of period                                                              $   56,944         $  340,386
                                                                                   ==========         ==========


Cash paid for:
  Interest                                                                         $   11,838         $    5,885
  Income Taxes                                                                              -                  -

Conversion of common shares to
  preferred shares                                                                 $    1,374         $        -

</TABLE>

<PAGE>


                                TRUE HEALTH, INC.
                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)



NOTE 1 - BASIS OF PRESENTATION

The accompanying unaudited interim financial statements of True Health, Inc.
("True Health") have been prepared in accordance with accounting principles
generally accepted in the United States of America and the rules of the
Securities and Exchange Commission ("SEC"), and should be read in conjunction
with the audited financial statements and notes thereto contained in True
Health, Inc.'s Annual Financial Statements filed with the SEC on Form 10-KSB and
in respect of the comparative period, the significant acquisition statement
filed with the SEC on Form 8-K. In the opinion of management, all adjustments,
consisting of normal recurring adjustments, necessary for a fair presentation of
financial position and the results of operations for the interim periods
presented have been reflected herein. The results of operations for interim
periods are not necessarily indicative of the results to be expected for the
full year. Notes to the financial statements which would substantially duplicate
the disclosure contained in the audited financial statements for the most recent
fiscal year end to January 31, 2005, as reported in the Form 10-KSB, have been
omitted.



NOTE 2 - PREFERRED SHARES

Effective March 19, a number of shareholders agreed to exchange their common
shares for Series A Convertible Preferred Shares which are to be held and
unavailable for sale for a period of one year. A total of 32,975,000 common
shares were exchanged in the way for 4,121,875 shares of Series A convertible
stock, including the shares of Mr D Francis, CEO.


NOTE 3 - REVERSE STOCK SPLIT

On April 18, 2005, True Health authorized a reduction in the total number of
shares of company's Common Stock at the ratio of one new share for sixty old
shares. This reverse stock split has been effected for all common share
information included in the financial statements.


NOTE 4 - SUBSEQUENT EVENTS

True Health entered into an agreement, whereby 22,000 Series A Convertible
Preferred Shares of $12.50 each were sold to external investors. The total
consideration of $275,000 is to be paid over a term, of which the first
instalment of $45,000 was received on May 2, 2005. Under the agreement, warrants
were also issued for the subscription for 600,000 shares at $0.125 each and for
6,250,000 shares at $0.04 each.



<PAGE>


ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

Important Information Regarding Forward-Looking Statements

This Quarterly Report on Form 10-QSB contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Those statements
include indications regarding our intent, belief or current expectations,
including our plans with respect to the sourcing, manufacturing, marketing and
distribution of our products and services, the belief that current levels of
cash and cash equivalents together with cash from operations and existing credit
facilities will be sufficient to meet its working capital requirements for the
next twelve months, our expectations with respect to the performance of the
counterparties to its letter of credit agreements, our plans to invest in
derivative instruments and the collection of accounts receivable, our beliefs
and intent with respect to and the effect of changes in financial accounting
rules on its financial statements. Such statements are subject to a variety of
risks and uncertainties, many of which are beyond the our control, which could
cause actual results to differ materially from those contemplated in such
forward-looking statements, which include, among other things, (i) changes in
the marketplace for our products and services, (ii) the introduction of new
products or pricing changes by our competitors, (iii) changes in exchange rates,
and (iv) changes in the economy. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. We undertake no obligation to update or revise
the information contained in this Quarterly Report on Form 10-QSB, whether as a
result of new information, future events or circumstances or otherwise.

Critical accounting policies

We have identified the policies below as critical to our business operations and
the understanding of our results of operations. The impact and any associated
risks related to these policies on our business operations is discussed
throughout Management's Discussion and Analysis of Financial Condition and
Results of Operations where such policies affect our reported and expected
financial results. The preparation of this Quarterly Report on Form 10-QSB
requires us to make estimates and assumptions that affect the reported amount of
assets and liabilities, disclosure of contingent assets and liabilities at the
date of our financial statements, and the reported amounts of revenue and
expenses during the reporting period. There can be no assurance that actual
results will not differ from those estimates.

1) Allowance for doubtful accounts

We evaluate the adequacy of the allowance for doubtful accounts at the end of
each quarter. In performing this evaluation, we analyze the payment history of
significant past due accounts, subsequent cash collections on these accounts and
comparative accounts receivable aging statistics. Based on this information,
along with consideration of the general strength of the economy, we develop what
we consider to be a reasonable estimate of the uncollectible amounts included in
accounts receivable. This estimate involves our significant judgment. Actual
uncollectible amounts may differ from our estimate.



2) Provision for obsolete inventory

We estimate our provision for obsolete inventory based on customer orders sold
below cost, to be shipped in the following period and on the amount of similar
unsold inventory at period end. We analyze recent sales and gross margins on
unsold inventory in further estimating the inventory provision. The impact of
the inventory provision is reflected in cost of sales and the related gross
margins in the period that management deems that inventory has become obsolete.
This estimate involves our significant judgment. Actual gross margins on sales
of excess inventory may differ from our estimate.


Three Months Ended April 30, 2005 Compared to Three Months Ended April 30, 2004

Revenue

Total revenue for the three months ended April 30, 2005 was $979,737. This
compares with revenues of $1,657,589 for the three months ended April 30, 2004
and represents a decrease of $677,852.

The equipment rentals and sales segment's revenue of $435,688 for the three
months ended April 30, 2005 represents a decrease of $60,687, when compared to
the revenues of $496,375 for the three months ended April 30, 2004. This change
reflects a stabalising of the equipment rentals market and a particularly high
sale in the comparable period of the previous year.

Revenue from the recruitment services and placement segment was $535,553 for the
three months ended April 30,2005. This represents a decrease of $615,522 when
compared with the comparable results for the three months ended April 30, 2004.
The main reason for the decrease arose from a change in recruitment personnel
during the last year and a concentration by management in developing a more
robust and sustainable business model. We believe that we are now in a much
stronger position to benefit from an increase in operations as a result of
improving the recruitment and candidate support process and by delivering a
higher quality of service than before.


Cost of sales

Cost of sales for the three months ended April 30, 2005, compared to the three
months ended April 30, 2004 are as follows:

<TABLE>
                                        Three months ended                 Three months ended
                                        April 30, 2005                     April 30, 2004
<S>                                     <C>                                <C>
Equipment rentals and sales               $184,845  34.5%                    $114,487  23.1%

Recruitment services and                   355,538  81.6%                     947,312  82.3%
- placement fees

Total                                   $  540,383  55.6%                  $1,061,799  64.1%
</TABLE>

Total cost of sales of $540,383 for the three months to April 30, 2005 was
$521,416 lower than the result for the three months ended April 30, 2004.
Overall, the costs as a proportion of revenues reduced to 55.6%, compared to
64.1%. This represents a success by management in reducing the variable cost
structure of the company, as well as having focussed of reducing fixed overhead
expenses.

General and administrative overheads

General and administrative overheads have decreased by $172,629 to $483,389 for
the three months to April 30, 2005, compared to overheads of $656,018 for the
three months to April 30, 2004. This represents a reduction of 26.3%. The main
reasons for the reduction are as follows:

Following the reverse merger of True Health and Westmeria Healthcare in mid-2003
the company's strategy had been to continue to concentrate on growing its
revenues. At that time it had undertaken an expansion programme to increase its
operations and administrative base to support such growth. As a result, the
expenditure associated with the increasing revenues experienced at that time had
led to a relatively high fixed cost structure, which resulted in its expenses
outweighing its revenues. During the course of the last year, the Company's
management continued to focus on revenues, which would generate a sustainable
and lasting, long-term benefit to overall shareholder value. Resultantly, a
shift in the cost base was made from that of high fixed costs to al lower cost
base, with a greater emphasis on professionalism and quality of service. The end
result has been to place the Company in a far greater position in terms of being
able to benefit from any future expansion in revenues, by ensuring that its
structural cost base remains efficient. Factors in reducing the levels of
expenditure for the three months ended April 30, 2005 as compared with that of
the same period last year, include:


o        A concentration on internally recruiting sales employees who have
         greater experience of meeting higher quality standards and delivering
         long-term client relationships with our customers,

o        A decrease in the expenses associated with managing and operating a
         publicly listed company following the additional experience gained by
         the board of directors in matters relating to the Securities Exchange
         Commission, public relations and marketing in general. This has
         resulted in a decrease in expenditure associated with external
         consultants.

o        Savings in expenditure associated with improvements in the logistical
         operations, following the investment in new IT software and systems
         development during the fourth quarter of 2004.



Interest expense


Net Interest expense of $11,838 for the three months to April 30, 2005,
increased by $8,831 compared with $3,017 for the three months to April 30, 2004.
This is mainly due to the reduction in funds available over the last year.


Liquidity and Capital Resources

We have relied primarily on asset-based borrowings, internally generated funds,
stockholder loans and trade credit to finance our operations. Our capital
requirements primarily result from working capital needed to support increases
in inventory and accounts receivable. Our working capital position has changed
from a deficit of $386,120 as of January 31, 2005 to a deficit of $396,360 as at
April 30, 2005. This is a moderate change and represents managements close
control over cash expenditure and cash flow over the period. As of April 30,
2005, we had cash and cash equivalents of $56,944 compared to $67,103 as of
January 31, 2005.


Operating Cash Flow

Net cash used in operating activities for the three months ended April 30, 2005
was $133,773 compared with net cash used of $239,193 for the three months ended
April 30, 2004. This increase represents an improvement of $105,420 represents
an improvement of 44.1% and is primarily due to the enhancement in service
delivery and control in overall operations.

Credit Facilities

We have a loan agreement with bankers, HSBC, for a term loan that advanced
(pound)130,000 in January 2003 and is due for repayment by November 2007. The
loan attracts variable rate interest of 2% over UK base rate and there is a
floating charge over the assets of the Company (67% at April 30, 2005).

We also have an accounts receivable factoring arrangement with Venture Finance,
which is secured by a floating charge over our assets. This facility has
attracts variable rate interest of 1.75% over UK base rate (6.50% at April 30,
2004).

We believe that current levels of cash and cash equivalents ($56,944 at April
30, 2005) together with cash from operations and funds available under our
credit facilities, together with fund to be raised from potential investors and
the support of the majority shareholder in the company, will be sufficient to
meet our capital requirements for the next 12 months.


ITEM 3. CONTROLS AND PROCEDURES

At April 30, 2005, we carried out an evaluation, under the supervision and with
the participation of our management, including our Chief Executive Officer and
Chief Financial Officer, of the effectiveness of the design and operation of our
disclosure controls and procedures pursuant to Rule 13a-14 under the Securities
Exchange Act of 1934, as amended. Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that our disclosure
controls and procedures are effective in timely alerting them to material
information relating to us required to be included in our periodic SEC filings.

There have been no significant changes in our internal controls or in other
factors that could significantly affect our controls subsequent to the date of
that evaluation, and no corrective actions with regard to significant
deficiencies and material weaknesses.


<PAGE>


                           PART II - OTHER INFORMATION



ITEM 6.    EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits Item Description
     31.1                  Certification Pursuant to Section 302 of the
                           Sarbanes-Oxley Act of 2002
     31.2                  Certification Pursuant to Section 302 of the
                           Sarbanes-Oxley Act of 2002
     32                    Certification Pursuant to 18 U.S.C. Section 1350, as
                           Adopted Pursuant to Section 906 of the Sarbanes-Oxley
                           Act of 2002

(b) Report on Form 10-KSB


TBA



                                                     SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.

         Dated:  June 14, 2005.

                                               TRUE HEALTH, INC.

                                               BY: David Francis
                                                  -------------------
                                                  David Francis, CEO



                                               BY: Ian Wylie
                                                   ------------------
                                                   Ian Wylie, CFO





<PAGE>



                                  Exhibit 31.1

                            Certification Pursuant to
                  Section 302 of the Sarbanes-Oxley Act of 2002

I, David Francis, certify that:

1.       I have reviewed the quarterly report on Form 10-QSB of True Health,
         Inc. for the period ended April 30, 2005 (this
         "Report");


2.          Based on my knowledge, this Report does not contain any untrue
            statement of a material fact or omit to state a material fact
            necessary to make the statements made, in light of the circumstances
            under which such statements were made, not misleading with respect
            to the period covered by this Report;


3.          Based on my knowledge, the financial statements, and other financial
            information included in this Report, fairly present in all material
            respects the financial condition, results of operations and cash
            flows of the registrant as of, and for, the periods presented in
            this Report;


4.          The registrant's other certifying officers and I are responsible for
            establishing and maintaining disclosure controls and procedures (as
            defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant
            and we have:

(a)         designed such disclosure controls and procedures to ensure that
            material information relating to the registrant, including its
            consolidated subsidiaries, is made known to us by others within
            those entities, particularly during the period in which this Report
            is being prepared;

(b)      evaluated the  effectiveness of the registrant's  disclosure  controls
         and procedures as of a date within 90 days prior to the
         filing date of this Report (the "Evaluation Date"); and


(c)         presented in this Report our conclusions about the effectiveness of
            the disclosure controls and procedures based on our evaluation as of
            the Evaluation Date;


     5. The registrant's other certifying officers and I have disclosed, based
     on our most recent evaluation, to the registrant's auditors and the audit
     committee of registrant's board of directors:
(a)           all significant deficiencies in the design or operation of
              internal controls which could adversely affect the registrant's
              ability to record, process, summarize and report financial data
              and have identified for the registrant's auditors any material
              weaknesses in internal controls; and
(b)           any fraud, whether or not material, that involves management or
              other employees who have a significant role in the registrant's
              internal controls; and


     6. The registrant's other certifying officers and I have indicated in this
     Report whether or not there were significant changes in internal controls
     or in other factors that could significantly affect internal controls
     subsequent to the date of our most recent evaluation, including any
     corrective actions with regard to significant deficiencies and material
     weaknesses.

Dated: June 14, 2005


David Francis
--------------------------------------
David Francis, CEO


                                  Exhibit 31.2

                            Certification Pursuant to
                  Section 302 of the Sarbanes-Oxley Act of 2002

I, Ian Wylie, certify that:

7.     I have reviewed the quarterly report on Form 10-QSB of True Health, Inc.
       for the period ended April 30, 2005 (this "Report");

8.     Based on my knowledge, this Report does not contain any untrue statement
       of a material fact or omit to state a material fact necessary to make the
       statements made, in light of the circumstances under which such
       statements were made, not misleading with respect to the period covered
       by this Report;

9.     Based on my knowledge, the financial statements, and other financial
       information included in this Report, fairly present in all material
       respects the financial condition, results of operations and cash flows of
       the registrant as of, and for, the periods presented in this Report;

10.    The registrant's other certifying officers and I are responsible for
       establishing and maintaining disclosure controls and procedures (as
       defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
       we have:

       (d)    designed such disclosure controls and procedures to ensure that
              material information relating to the registrant, including its
              consolidated subsidiaries, is made known to us by others within
              those entities, particularly during the period in which this
              Report is being prepared;
       (e)    evaluated the effectiveness of the registrant's disclosure
              controls and procedures as of a date within 90 days prior to the
              filing date of this Report (the "Evaluation Date"); and
       (f)    presented in this Report our conclusions about the effectiveness
              of the disclosure controls and procedures based on our evaluation
              as of the Evaluation Date;

11.    The registrant's other certifying officers and I have disclosed, based on
       our most recent evaluation, to the registrant's auditors and the audit
       committee of registrant's board of directors: (c) all significant
       deficiencies in the design or operation of internal controls which could
       adversely affect the registrant's
              ability to record, process, summarize and report financial data
              and have identified for the registrant's auditors any material
              weaknesses in internal controls; and
       (d)    any fraud, whether or not material, that involves management or
              other employees who have a significant role in the registrant's
              internal controls; and

12.    The registrant's other certifying officers and I have indicated in this
       Report whether or not there were significant changes in internal controls
       or in other factors that could significantly affect internal controls
       subsequent to the date of our most recent evaluation, including any
       corrective actions with regard to significant deficiencies and material
       weaknesses.


Dated: June 14, 2005


Ian Wylie
--------------------------------------
Ian Wylie, CFO



                                   Exhibit 32

         Certification Pursuant to 18U.S.C Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

Each   of the undersigned hereby certifies, for the purposes of section 1350 of
       chapter 63 of title 18 of the United States Code, in his capacity as an
       officer of True Health, Inc. ("True Health"), that, to his knowledge, the
       quarterly report on Form 10-QSB of True Health, Inc. for the period ended
       April 30, 2005, fully complies with the requirements of Section 13(a) of
       the Securities Exchange Act of 1934 and that the information contained in
       such amendment to said report fairly presents, in all material respects,
       the financial condition and results of operation of True Health.

Dated: June 14, 2005




David Francis
--------------------------------------
David Francis, CEO




Ian Wylie
--------------------------------------
Ian Wylie, CFO